Corporation (NASDAQ: CTSH) has announced the expansion of its partnership with biopharmaceutical company Gilead Sciences (NASDAQ: NASDAQ:GILD), aiming to enhance Gilead's customer service, employee ...

Gilead is expected to enhance its efficiency through leveraging Cognizant’s expertise in AI and advanced technology ...

HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of a curative regimen for human immunodeficiency virus (HI ...

Mobility, an autonomous vehicle (AV) technology company, announced an alliance relationship to bring new data and insight ...

Cognizant (NASDAQ: CTSH) has announced an expansion of its longstanding relationship with biopharmaceutical leader Gilead Sciences (NASDAQ: GILD) that aims to unlock even greater value for Gilead as ...

HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of ...

DelveInsight's Inflammatory Bowel disease market Report provides comprehensive insights into the epidemiology and market dynamics across the 7MM. LAS VEGAS , NV, UNITED STATES, January 30, 2025 ...

Wells Fargo analyst Mohit Bansal downgraded Vertex Pharmaceuticals (VRTX) to Equal Weight from Overweight with an unchanged price target of ...

A young parolee brings unforeseen magic to a forlorn little town in “The Spitfire Grill,” running at Ross Valley Players through Feb. 23.

Gilead Sciences, Inc. (NASDAQ:GILD), a leading biopharmaceutical company with a market capitalization of $119.32 billion, has been making significant strides in its core HIV franchise while expanding ...

The Mount Gilead Exempted Village Schools Board of Education met Jan. 13 for both organizational and regular board meetings. One of the first orders of business was to approve meeting times for the ...

Gilead Sciences Inc. closed 3.35% below its 52-week high of $98.90, which the company achieved on November 11th.